For the first time, the U.S. Food and Drug Administration (FDA) has approved the use of a ketamine-like drug as a stand-alone therapy for adults with treatment-resistant depression (TRD).
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar ...
Esketamine, the chemical name for Spravato, is a chemical mirror image of anesthetic ketamine, which is also abused as a recreational party drug and goes by the street nickname “Special K”.
The US Food and Drug Administration (FDA) has approved the use of esketamine nasal spray as a standalone treatment for adults with major depressive disorder (MDD) who have not responded adequately ...
Spravato is made from esketamine, one of two mirror-image molecules found in ... The original approval required that patients on Spravato also receive an oral antidepressant. Now, the FDA says the ...
The FDA has approved Janssen’s antidepressant ... who have cycled through multiple treatments without relief. Spravato (esketamine) has been touted as a potential blockbuster for Janssen ...
“Hopefully, this approval by the FDA shows that there is sufficient evidence for esketamine working that providers and patients and their families will be comfortable and more confident that in ...
After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...
However, it may cover Spravato, which contains esketamine. This is an FDA-approved drug that derives from ketamine and can help manage treatment-resistant depression. Despite not yet having FDA ...
Alert FDA OKs Esketamine Nasal Spray Monotherapy for Depression The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not responded ...
Spravato is made from esketamine, one of two mirror-image molecules ... on Spravato also receive an oral antidepressant. Now, the FDA says the drug can be used on its own. The decision came ...